BC068157 Inhibitors
BC068157, a protein intricately involved in cellular processes, is associated with diverse functions, including angiogenesis, DNA repair, and cellular signaling. Functionally, BC068157 is implicated in regulating crucial aspects of cellular homeostasis, making it a key player in various cellular pathways. The general mechanisms of inhibition for BC068157 inhibitors involve targeted disruptions of specific molecular interactions or signaling pathways. For instance, Axitinib indirectly influences BC068157 by targeting VEGFR-mediated angiogenic signaling. By disrupting downstream events in angiogenesis, Axitinib indirectly modulates BC068157-associated cellular processes, illustrating the interconnected nature of angiogenic pathways and BC068157 function.
Furthermore, Nutlin-3 indirectly impacts BC068157 by disrupting the p53-MDM2 interaction, influencing BC068157 through alterations in MDM2-mediated cellular processes. This indirect modulation emphasizes the interconnectedness of protein-protein interactions and BC068157-associated pathways. Dasatinib, by targeting Src kinase, indirectly influences BC068157-associated signaling events, illustrating its indirect impact on BC068157 by disrupting specific protein-protein interactions within kinase pathways. In addition, Wortmannin, a PI3K inhibitor, indirectly inhibits BC068157 by disrupting the PI3K/AKT pathway. This disruption affects BC068157-associated cellular processes and downstream signaling events, highlighting the interconnected nature of kinase pathways and the indirect modulation of BC068157 by Wortmannin. Epigenetic modulators like GSK-J4 and Trichostatin A directly influence BC068157 by modulating histone demethylation and acetylation, respectively. These actions on chromatin structure directly affect BC068157-mediated gene regulation, emphasizing the role of epigenetic modifications in BC068157-associated cellular processes. The diverse mechanisms of inhibition collectively illustrate the complexity of BC068157's involvement in cellular processes and offer insights into potential avenues for targeted interventions in various pathways.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
(–)-Nutlin-3 | 675576-98-4 | sc-222086 sc-222086A | 1 mg 5 mg | $122.00 $219.00 | 2 | |
Nutlin-3, a p53/MDM2 inhibitor, indirectly influences BC068157 by disrupting the p53-MDM2 interaction. BC068157 interacts with MDM2, and Nutlin-3's action on this interaction indirectly impacts BC068157 through alterations in MDM2-mediated cellular processes. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Dasatinib, a Src/Abl kinase inhibitor, indirectly influences BC068157 by targeting Src kinase. BC068157 interacts with Src, and Dasatinib's inhibition disrupts this interaction, indirectly modulating BC068157-associated signaling events. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
MG-132, a proteasome inhibitor, indirectly influences BC068157 by preventing proteasomal degradation. BC068157 turnover is regulated by the proteasome, and MG-132's action on the proteasome indirectly stabilizes BC068157, influencing its cellular functions related to protein degradation and turnover. | ||||||
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $82.00 $216.00 $416.00 | 48 | |
SB-431542 acts as an indirect inhibitor by targeting the TGF-β/Smad pathway. While avoiding direct modulation of TGF, it impacts downstream signaling events connected to BC068157. By influencing the TGF-β/Smad pathway, SB-431542 indirectly modulates BC068157 function, illustrating the interconnectedness of signaling cascades in cellular processes. | ||||||
GSK-J4 | 1373423-53-0 | sc-507551 | 100 mg | $1275.00 | ||
GSK-J4, a JMJD3 histone demethylase inhibitor, directly influences BC068157 by modulating histone demethylation. BC068157 associates with chromatin, and GSK-J4's action on JMJD3 alters histone demethylation patterns, directly affecting BC068157-mediated gene regulation. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin, a phosphoinositide 3-kinase (PI3K) inhibitor, indirectly inhibits BC068157 by disrupting the PI3K/AKT pathway. BC068157 interacts with AKT, and Wortmannin's action on PI3K interferes with this interaction, indirectly affecting BC068157-associated cellular processes and downstream signaling events. | ||||||
Veliparib | 912444-00-9 | sc-394457A sc-394457 sc-394457B | 5 mg 10 mg 50 mg | $182.00 $275.00 $726.00 | 3 | |
Veliparib, a PARP inhibitor, directly targets BC068157 by inhibiting PARP enzymatic activity. BC068157 is involved in DNA repair processes, and Veliparib's inhibition of PARP interferes with DNA repair, directly affecting BC068157-mediated repair mechanisms. | ||||||
AZD7762 | 860352-01-8 | sc-364423 | 2 mg | $107.00 | ||
AZD7762, a CHK1 inhibitor, indirectly influences BC068157 by disrupting the CHK1-mediated DNA damage response. BC068157 is involved in DNA repair pathways, and AZD7762's action on CHK1 interferes with downstream signaling events, indirectly impacting BC068157-associated cellular processes. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002, a PI3K inhibitor, indirectly influences BC068157 by disrupting the PI3K/AKT pathway. BC068157 interacts with AKT, and LY294002's action on PI3K interferes with this interaction, indirectly affecting BC068157-associated cellular processes and downstream signaling events. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
Trichostatin A, an HDAC inhibitor, indirectly inhibits BC068157 by modulating histone acetylation. BC068157 associates with chromatin, and Trichostatin A's action on HDACs alters chromatin structure, indirectly influencing BC068157-mediated gene regulation. | ||||||